[go: up one dir, main page]

MXPA06002648A - Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades medidas por cox-2. - Google Patents

Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades medidas por cox-2.

Info

Publication number
MXPA06002648A
MXPA06002648A MXPA06002648A MXPA06002648A MXPA06002648A MX PA06002648 A MXPA06002648 A MX PA06002648A MX PA06002648 A MXPA06002648 A MX PA06002648A MX PA06002648 A MXPA06002648 A MX PA06002648A MX PA06002648 A MXPA06002648 A MX PA06002648A
Authority
MX
Mexico
Prior art keywords
milk
treating
mediated diseases
cyclooxygenase
preparations
Prior art date
Application number
MXPA06002648A
Other languages
English (en)
Inventor
Catherine Mace
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06002648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MXPA06002648A publication Critical patent/MXPA06002648A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)

Abstract

La presente invencion se relaciona a composiciones nutricionales y farmaceuticas para el tratamiento y prevencion de enfermedades mediadas por la ciclooxigenasa 2 y a un proceso para incrementar la actividad inhibidora de ciclooxigenasa 2 de un producto. Ademas de ello, la presente invencion se refiere al uso de una o mas fracciones de proteina de leche y/o una o mas preparaciones de proteina de leche para inhibir la actividad de ciclooxigenasa 2 (COX-2), en particular para la preparacion de un medicamento o un alimento funcional para el tratamiento y la prevencion de enfermedades mediadas por la ciclooxigenasa 2.
MXPA06002648A 2003-09-12 2004-09-13 Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades medidas por cox-2. MXPA06002648A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03020739.3A EP1514482B2 (en) 2003-09-12 2003-09-12 Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases
PCT/EP2004/010200 WO2005025335A1 (en) 2003-09-12 2004-09-13 Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases

Publications (1)

Publication Number Publication Date
MXPA06002648A true MXPA06002648A (es) 2006-06-05

Family

ID=34130196

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06002648A MXPA06002648A (es) 2003-09-12 2004-09-13 Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades medidas por cox-2.

Country Status (16)

Country Link
US (1) US8012509B2 (es)
EP (2) EP1514482B2 (es)
JP (1) JP4824560B2 (es)
CN (1) CN1849076B (es)
AR (1) AR045745A1 (es)
AT (1) ATE407574T2 (es)
AU (1) AU2004271722B2 (es)
BR (1) BRPI0413714A (es)
CA (1) CA2537544C (es)
CR (1) CR8265A (es)
DE (1) DE60323489D1 (es)
ES (1) ES2314152T3 (es)
MX (1) MXPA06002648A (es)
PT (1) PT1514482E (es)
TW (1) TW200524545A (es)
WO (1) WO2005025335A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515929A (ja) * 2005-11-14 2009-04-16 ネステク ソシエテ アノニム 糖化タンパク質を用いた経口免疫寛容促進
NL1033698C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
US20080293159A1 (en) * 2007-05-24 2008-11-27 Murray Goulburn Co-Operative Co. Ltd. Validation Process
KR20120089725A (ko) * 2009-10-16 2012-08-13 우먼'스 앤드 칠드런'스 헬스 리서치 인스티튜트 산 처리 수성 유청 단백질 추출물을 사용하는 알레르기 치료 방법
WO2012050895A1 (en) * 2010-09-28 2012-04-19 Lisa Geng Methods for treating neurological disorders using nutrient compositions
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
CN105613731B (zh) * 2016-03-17 2019-12-31 广西壮族自治区水牛研究所 一种发酵乳制品
WO2019229215A2 (de) * 2018-05-30 2019-12-05 DÖHLER GmbH Hochdruckverfahren, insbesondere zur haltbarmachung von lebensmitteln, pharmazeutika und kosmetika, sowie hochdruckvorrichtung
WO2020159357A1 (en) * 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748847A1 (de) * 1976-11-05 1978-05-11 Stauffer Chemical Co Verfahren zum verstaerken saurer alkoholfreier getraenke mit protein und verstaerkungsmittel auf proteinbasis
US4358464A (en) * 1977-08-02 1982-11-09 Superior Dairy, Inc. Process for converting sour whey into sweet whey and product
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
DE3141914A1 (de) * 1981-10-22 1983-05-05 Babcock-BSH AG vormals Büttner-Schilde-Haas AG, 4150 Krefeld Verfahren zur herstellung von frischkaese
JPS6339545A (ja) * 1986-08-04 1988-02-20 Meiji Milk Prod Co Ltd 牛乳ホエ−中のβ−ラクトグロブリンの除去方法
JP2622686B2 (ja) * 1987-05-15 1997-06-18 雪印乳業株式会社 ｋ−カゼイングリコマクロペプチドの製造法
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
US5888552A (en) 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DE4413839C1 (de) * 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
DE19649891C2 (de) * 1996-12-02 1998-12-10 Mk Produktkontor Gmbh Verwendung von antioxidativen Zusammensetzungen mit Süßmolkekonzentrat
DE19726868A1 (de) * 1997-06-24 1999-01-07 Mk Produktkontor Gmbh Antioxidative Zusammensetzungen mit Süßmolkekonzentrat
JP2002517454A (ja) * 1998-06-10 2002-06-18 アルバート ビー クラム 健康保護性腸管ミクロフローラの創造／維持及び免疫系の増強のための予防的及び治療的栄養サプリメント
US6558716B1 (en) * 1999-01-14 2003-05-06 Kraft Foods Holdings, Inc. Process for incorporating whey protein into cheese
DE19918210A1 (de) 1999-04-22 2000-11-02 Biomun Gmbh Verfahren zur Herstellung eines Milchpräparates mit verzögerter Inhaltsstoff-Freisetzung und seine Verwendung
DE19918219C1 (de) * 1999-04-22 2001-01-18 Dornier Gmbh Lebensdauer-Indikator für hochbeanspruchte Leichtbau-Strukturen
PL199861B1 (pl) * 1999-04-29 2008-11-28 Nestle Sa Preparat dla niemowląt i sposób wytwarzania preparatu
US6469063B1 (en) * 1999-11-18 2002-10-22 City Of Hope Inhibition of inflammation via inhibition of COX-2 gene transcription
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
FR2808444B1 (fr) 2000-05-05 2004-03-26 Francois Ballestra Utilisation d'une fraction du lait d'equide pour la fabrication d'une composition possedant une activite d'inhibition de la production de l'interleukine-1 et composition ainsi obtenue
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
PL366226A1 (en) * 2000-12-22 2005-01-24 Societe Des Produits Nestle S.A. Induction of tolerance
US20020169195A1 (en) * 2001-01-26 2002-11-14 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
US6589574B2 (en) * 2001-03-19 2003-07-08 Council Of Scientific & Industrial Research Process for preparation of protein-hydrolysate from milk protein
US20030026845A1 (en) * 2001-06-18 2003-02-06 Etzel Lisa R. Process for preparing protein isolate from milk, whey, colostrum, and the like
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
DE10208034A1 (de) 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt

Also Published As

Publication number Publication date
DE60323489D1 (de) 2008-10-23
JP2007505078A (ja) 2007-03-08
CN1849076A (zh) 2006-10-18
CN1849076B (zh) 2010-06-09
EP1955602A1 (en) 2008-08-13
TW200524545A (en) 2005-08-01
BRPI0413714A (pt) 2006-10-17
US20070110818A1 (en) 2007-05-17
ES2314152T3 (es) 2009-03-16
CA2537544C (en) 2012-12-11
JP4824560B2 (ja) 2011-11-30
AU2004271722B2 (en) 2010-12-16
AR045745A1 (es) 2005-11-09
EP1955602B1 (en) 2018-04-04
ATE407574T2 (de) 2008-09-15
CA2537544A1 (en) 2005-03-24
WO2005025335A1 (en) 2005-03-24
EP1514482A1 (en) 2005-03-16
PT1514482E (pt) 2008-11-19
EP1514482B2 (en) 2016-06-22
CR8265A (es) 2006-07-14
EP1514482B1 (en) 2008-09-10
AU2004271722A1 (en) 2005-03-24
US8012509B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
Žugčić et al. From extraction of valuable compounds to health promoting benefits of olive leaves through bioaccessibility, bioavailability and impact on gut microbiota
Pirro et al. Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA)
Agyei et al. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2002047703A8 (en) Immune system stimulation
JP6524176B2 (ja) プロリルオリゴペプチダーゼ阻害剤
BG105856A (bg) Използване на хидроксиматерезинол за предотвратяване на рак
BRPI0515618A (pt) cepa de lactobacillus plantarum, composição para produzir cla, processo para produção em massa de cla alimento funcional redutor de corpos de gordura, produtos diários, alimentos fermentados, medicamento para prevenção e tratamento de doenças relacionadas com a obesidade
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2007113008A3 (en) Opaque container comprising food or pharmaceutical products or herbal(s)
MXPA06002648A (es) Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de las enfermedades medidas por cox-2.
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
TW200505470A (en) Therapeutic agent
WO2005082927A3 (en) Antihypertensive peptides
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
TW200602073A (en) Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a DPP-IV mediated condition
AU2003202616A1 (en) Improved pasta product and method for preparation thereof
TW200612903A (en) Use of trisubstituted benzopyranones
KR101418968B1 (ko) ＣＨＰ(ｃｙｃｌｏ(Ｈｉｓ-Ｐｒｏ))를 고농도로 함유한 대두 가수분해물을 포함하는 혈당 조절용 조성물
WO2005074989A3 (en) Combination of a dna topoisomerase inhibitor and an iap inhibitor
WO2004006911A3 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
El-Sayed et al. Purification of a novel monophenolase inhibitory peptides prepared from Vicia faba pods protein via enzymatic hydrolysis
PT1796702E (pt) Utilização de óleo de lavanda para profilaxia e tratamento de distúrbios de somatização e da doença de stress pós-traumático
PL1615656T3 (pl) Produkt immunomodulatorowy otrzymany z hodowli bifidobacterium i zawierające go kompozycje
UA94434C2 (ru) Экстракт коры дерева рода corynanthe и его применение, лекарственное средство, пищевой продукт с лекарственными или профилактическими свойствами и фармацевтический препарат, который его содержит

Legal Events

Date Code Title Description
FG Grant or registration